Arcus Biosciences, Inc. (RCUS) Form 8-K — Aug 5, 2026
Arcus Biosciences reported a second-quarter 2026 net loss of $91 million, or $(0.72) per share, versus roughly breakeven a year earlier, as revenue fell to $41 million from $160 million — the year-ago quarter having included a $143 million one-time license catch-up tied to etrumadenant. Cash, cash equivalents and marketable securities stood at $775 million at June 30, 2026, down from about $1.0 billion at year-end 2025, and management guided to roughly $600 million of cash at year-end 2026 with runway into at least the second half of 2028.
Key figures
- Revenue
- $41 million (Q2 2026)
- Guidance
- FY2026 GAAP revenue of $65-75 million; year-end 2026 cash of approximately $600 million; cash runway until at least the second half of 2028
- Net Income
- -$91 million (Q2 2026) vs $0 in Q2 2025
- Revenue Yoy
- Down from $160 million in Q2 2025, which included a $143 million one-time license/development catch-up related to etrumadenant
- Total Assets
- $924 million
- Cash Position
- $775 million as of June 30, 2026 (vs $1,010 million at Dec 31, 2025)
- Total liabilities
- $460 million
- Ga expense q2 2026
- $24 million (vs $29 million in Q2 2025)
- Stock comp q2 2026
- $9 million R&D plus $6 million G&A
- Rnd expense q2 2026
- $113 million (vs $139 million in Q2 2025)
- Stockholders equity
- $464 million
- Weighted basic shares
- 126.1 million
- Revenue six months 2026
- $58 million (vs $188 million in H1 2025)
- Taiho milestone q3 2026
- $15 million
- Net loss six months 2026
- $219 million (vs $112 million in H1 2025)
- Partner reimbursements q2 2026
- $17 million (vs $33 million in Q2 2025)
Price after filing
Close on the filing date to close N calendar days later (from $28.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.